No evidence of risk, although adequate, well-controlled studies in humans have not been carried out.
Animal studies show no teratogenicity.
As is true of rifampin, rifabutin can induce hepatic enzymes that decrease the activity of other drugs, including clarithromycin. Reduces activity of dapsone, methadone, narcotics, anticoagulants, corticosteriods, cyclosporine, cardiac glycosides, quinidine, oral contraceptives, oral hypoglycemics, and analgesics. May also decrease effect of ketaconazole, diazepam, barbiturates, verpamil, beta-adrenergic blockers, clofibrate, progestins, disopyramide, mexiletine, theophyllin, chloramphenicol, and anticonvulsants. Rifabutin decreases plasma concentrations of ZDV, but not of fluconazole or ddI. Fluconazole may increase serum concentrations of rifabutin. Tuberculosis organisms which are resistant to rifampin will be resistant to rifabutin, and vice versa.